Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Proshares Trust (ZBIO) Free Cash Flow (2023 - 2025)

Historic Free Cash Flow for Zenas BioPharma (ZBIO) over the last 3 years, with Q3 2025 value amounting to -$41.1 million.

  • Zenas BioPharma's Free Cash Flow fell 3240.93% to -$41.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$158.6 million, marking a year-over-year decrease of 6418.51%. This contributed to the annual value of -$119.8 million for FY2024, which is 29221.17% down from last year.
  • Zenas BioPharma's Free Cash Flow amounted to -$41.1 million in Q3 2025, which was down 3240.93% from -$41.7 million recorded in Q2 2025.
  • Over the past 5 years, Zenas BioPharma's Free Cash Flow peaked at -$15.4 million during Q4 2023, and registered a low of -$41.7 million during Q2 2025.
  • Over the past 3 years, Zenas BioPharma's median Free Cash Flow value was -$34.1 million (recorded in 2024), while the average stood at -$31.9 million.
  • As far as peak fluctuations go, Zenas BioPharma's Free Cash Flow plummeted by 15083.12% in 2024, and later tumbled by 3240.93% in 2025.
  • Quarter analysis of 3 years shows Zenas BioPharma's Free Cash Flow stood at -$15.4 million in 2023, then plummeted by 150.83% to -$38.6 million in 2024, then dropped by 6.46% to -$41.1 million in 2025.
  • Its Free Cash Flow was -$41.1 million in Q3 2025, compared to -$41.7 million in Q2 2025 and -$37.1 million in Q1 2025.